Alzheimer's Drug Kisunla Faces Mixed Reception in UK

Britain's drug regulator approved Kisunla for Alzheimer's treatment, yet an independent agency deemed it too costly for NHS funding. Similar treatment, Leqembi, faced the same issue. NICE demands more evidence on efficacy and cost-effectiveness. Patients can access the drug privately.

The UK's drug regulator granted approval for Kisunla, an Alzheimer's medication, while an independent assessment body rejected its NHS funding on grounds of cost. The approval marks the second Alzheimer's drug facing a split decision in a short span.

Despite the Medicines and Healthcare products Regulatory Agency's endorsement of Kisunla, also known as donanemab, NICE argues that the drug's high price tag, compounded by intravenous administration and side effects like brain swelling, makes it fiscally inadvisable for taxpayers.

An ongoing dialogue between the drug's makers, Eli Lilly, and healthcare systems is anticipated, with expectations of refined evidence addressing NICE concerns. Alzheimer's Society and the academic community acknowledge both the disapproval and the necessity for innovative treatment avenues.

(With inputs from agencies.)